



上海昊海生物科技股份有限公司

Shanghai Haohai Biological Technology Co., Ltd.

(a joint stock company incorporated in the People's Republic of China with limited liability)

Stock Code : 6826



Environmental, Social
and Governance Report
2020



CONTENTS

About This Report 2

01

About Haohai

1.1 Highlights in 2020	5
1.2 Economic values	6

02

Dedicated to Corporate Governance

2.1 Corporate governance	8
2.2 Anti-Corruption and business integrity	9
2.3 Materiality analysis	9

03

Devoted to Product Development

3.1 Innovative development	12
3.2 Quality assurance	14
3.3 Responsible marketing	16

04

Environmental Protection

4.1 Environmental management	18
4.2 Energy conservation and consumption reduction	18
4.3 Compliant emissions	21

05

Harmonious Team

5.1 Overview of employees	26
5.2 Development of employees	27
5.3 Health and safety	28
5.4 Caring for staff	29

06

Heart in Community

6.1 Charity donations	31
6.2 Contributions to the industry	31
6.3 Assistance to fight against COVID-19 pandemic	32

Appendix – Content Index of ESG Reporting Guide of the Stock Exchange... 34

About This Report

Scope of the report

This report is the fifth Environmental, Social and Governance (“**ESG**”) Report released by Shanghai Haohai Biological Technology Co., Ltd. It focuses on the disclosure of information regarding the Company’s economic, social and environmental aspects during the reporting period from 1 January 2020 to 31 December 2020 (the “**Reporting Period**”), and some contents involve the information prior to 2020.

Unless otherwise stated, environmental KPIs specified in this report mainly cover the Company and its domestic subsidiaries which are engaged in product research and development (“**R&D**”), production and sales (the “**Domestic Subsidiaries**”). During the Reporting Period, the operating revenue of the Company and its Domestic Subsidiaries accounted for approximately 83.64% of the Group’s total revenue; as of the end of the Reporting Period, the total assets of the Company and its Domestic Subsidiaries made up approximately 94.62% of the Group’s total assets. However, general disclosures and compliance matters cover the Company and all of its subsidiaries. The Group will continuously assess the range of material ESG operations of different business segments or its key subsidiaries, and determine whether they should be included into the scope of the ESG Report.

Unless otherwise stated, the currency mentioned in this report refers to Renminbi (“**RMB**”).

Basis for compilation of the report

This report is compiled with reference to the “Environmental, Social and Governance Reporting Guide” (the “**ESG Reporting Guide**”) under Appendix 27 to the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong (the “**Hong Kong Listing Rules**”) issued by the Stock Exchange of Hong Kong Limited (the “**SEHK**”).

Relevant abbreviations

For the convenience of presentation and reading, the following abbreviations are used in this report:

“The Company” or “Haohai Biological”	Shanghai Haohai Biological Technology Co., Ltd.
“The Group”, “we”, “us” and “our”	The Company and its subsidiaries
“GMP”	Good Manufacturing Practice
“Hangzhou Aijinglun”	Hangzhou Aijinglun Technology Co., Ltd., a non-wholly owned subsidiary of the Company
“NIMO”	Shenzhen New Industries Material of Ophthalmology Co., Ltd., a non-wholly owned subsidiary of the Company
“NMPA”	National Medical Products Administration of the People’s Republic of China
“Shanghai Likangrui”	Shanghai Likangrui Bioengineering Co., Ltd., a wholly-owned subsidiary of the Company
“Shanghai Jianhua”	Shanghai Jianhua Fine Biological Preparations Co., Ltd., a wholly-owned subsidiary of the Company
“Shanghai Qisheng”	Shanghai Qisheng Biologicals Co., Ltd., a wholly-owned subsidiary of the Company

About This Report

Sources of data and assurance of reliability

The data and cases contained in this report are mainly derived from the Group's statistical reports and related documents. The Group undertakes that this report does not contain any false records or misleading statements.

Confirmation and approval

After being confirmed by the management of the Company, this report was approved by the board of directors (the **"Board"**) of the Company on 23 April 2021.

Access to and feedback on the report

This report is available in traditional Chinese and English versions. The electronic version of this report is available for download at the SEHK's website (www.hkexnews.hk) and the Company's website (www.3healthcare.com).

We take the opinions of stakeholders very seriously and welcome readers to contact us using the following contact information. Your opinions will help us further improve this report and enhance the overall environmental, social and governance performance of the Group.

Address: 23/F, Wen Guang Plaza, No. 1386 Hongqiao Road, Changning District, Shanghai, PRC

Tel: +86 21 52293555

Fax: +86 21 52293558

Email: info@3healthcare.com

Website: <http://www.3healthcare.com/>

01




ABOUT HAOHAI

Founded in 2007, the Company focuses on the research and development, manufacturing and sales of biomedical materials. We strategically target the fast-growing therapeutic areas in the biomedical material market in China, including ophthalmology, medical aesthetics and wound care, orthopedics, anti-adhesion and hemostasis. The Company was successfully listed on the Main Board of HKEX on 30 April 2015 (stock code: 06826.HK). On 30 October 2019, the Company was listed on the Sci-tech Innovation Board of the Shanghai Stock Exchange (the “**STAR Market**”) (stock code: 688366.SH), making us the first biopharmaceutical company listed on both the SEHK and the STAR Market.




1.1 Highlights in 2020



About Haohai

1.2 Economic values



Earnings
per share:

RMB

1.30



Net profit
attributable to
the parent:

RMB


230.07
million



Gross profit
margin:

74.78%

02



Dedicated to Corporate Governance

Through dedicated corporate governance and ESG management, the Group strives to enhance the corporate value, safeguard the interests of shareholders, and actively implement sustainable development. We continue to improve the corporate governance, strengthen risk management and control, and insist on honest operation and scientific development to ensure the stable development of the Group. We integrate ESG concepts into daily management, and always strive to build a sound ESG management system. By strengthening the communications with stakeholders, we understand the stakeholders' concerns on the Group, thus helping the Group to achieve long-term development.



Dedicated to Corporate Governance

2.1 Corporate governance

Company governance

The Company established a corporate governance structure consisting of the shareholders' general meeting, Board, Supervisory Committee and the management, and formulated mechanisms of mutual coordination and checks and balances characterized by a clear division of power and responsibility between the governing, decision-making and supervisory bodies and the management, and well-regulated operations in accordance with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Code of Corporate Governance for Listed Companies promulgated by China Securities Regulatory Commission, the Listing Rules of the Sci-Tech Innovation Board of the Shanghai Stock Exchange, the Corporate Governance Code as set out in Appendix 14 of the Hong Kong Listing Rules and other relevant laws, regulations and normative documents. The Company's Board has established special subordinate committees, including a strategic committee, an audit committee, a nomination committee and a remuneration and review committee, which assist and supervise the Board in making decisions on strategic development, audit, human resources management and remuneration.

Please refer to the "Corporate Governance Report" chapter of the 2020 annual report of the Company for further details about corporate governance.

ESG management

The Group has deepened the integration of ESG responsibility concepts and business strategies by introducing ESG concepts into corporate management. In order to continuously improve the Group's ESG management level, we actively encourage and support the relevant ESG report compiling personnel to participate in external ESG trainings.

During the Reporting Period, in order to implement ESG management work in an effective manner, the Company has established an ESG management structure consisting of the Board and the ESG working group to guarantee the continuous and effective implementation of the Group's ESG management work. Full-time staff are deployed to conduct communication, data collection and preparation for compilation of the report in respect of ESG relevant issues. The ESG working group is responsible for the specific implementation of the ESG business and giving feedback to the management of the Company. The management of the Company reports to the Board to help them evaluate and determine in a timely manner whether the risk management and internal control system of ESG are appropriate and effective. In the future, we will continue to promote the in-deep participation of the Board in the ESG risk assessment and management procedures, and continue to improve the scientific and systematic ESG management.

Dedicated to Corporate Governance

2.2 Anti-Corruption and business integrity

The Group has formulated the anti-fraud and whistle-blowing system, adopted a reporting system for conflict of interests and the code of conduct against sales-related corruptions and other relevant systems, clearly enumerated the prohibited behaviors, and requires sales staff to sign undertakings for corruption-free sales to increase the awareness of integrity and self-discipline among employees. We have also valued publicity and training on anti-corruption and anticorruption bribery for key positions. We protect the rights of whistle-blowing of all staff to report corruption cases by providing a variety of reporting channels, such as telephone hotline, mail box, etc. to prevent the occurrence of corruption cases. When receiving complaints or whistle-blowing information, the audit department of the Company shall report to the general manager of the Company and the Board respectively according to the position of the respondent or the person has been reported, and shall conduct further investigation and handle the matters; the audit department shall notify the complainant or whistleblower of the outcome of the investigation.

During the Reporting Period, the Group complied with the Criminal Law of the People's Republic of China, the Law of the People's Republic of China against Unfair Competition and other relevant laws and regulations against corruption (including prevention of bribery, extortion, fraud and money laundering), and was not involved in any corruption-related lawsuits.

2.3 Materiality analysis

Communication with stakeholders

The Group has been committed to establishing communication and exchanges with stakeholders. Through various channels of communication with various categories of stakeholders, we seek in-depth understanding of the needs of all parties, collecting opinions from them, sharing and discussing different issues closely related to the development of the Group. We strive to integrate the feedback and expectations of stakeholders with the formulation of the Group's ESG management strategy and policy, so as to realize the sustainable development of the Group. The following table sets out the composition of the stakeholders of the Group and the topics that are of particular interest to them during the Reporting Period.

Stakeholders	Topics of concern to stakeholders	Communication and feedback channels
Customers	R&D and innovation, product safety and service quality	Complaint hotline, customer satisfaction survey, industry association membership, etc.
Shareholders	Business performance, regulatory compliance, R&D and innovation	Shareholders meeting, information disclosure, and reception of investigations and surveys
Government and regulators	Regulatory compliance, R&D and innovation, environmental protection	Legal and regulatory compliance in business operations, reception for site inspections and reporting, and filing for government projects
Employees	Remuneration and benefits, career development, and humanistic solicitude	Staff medical checkup, professional training, and teambuilding events
Suppliers	Honesty and business integrity, and supplier management	Procurement tender, performance appraisal and evaluation, and suppliers meetings
Community	Communication with communities, environmental protection, product safety	Involvement in community events, and reception of interviews or surveys

Dedicated to Corporate Governance

Materiality analysis

Based on the ESG Reporting Guidelines and peer benchmarking, we formulated an ESG materiality issues matrix after taking into account our in-depth research and investigation in the industry and the feedbacks on different issues collected from various stakeholders. During the Reporting Period, we identified a total of 26 materiality issues to establish the ESG materiality issues matrix as shown below, which clearly shows the different degree of concern on different issues by internal and external stakeholders of the Group.




No.	Name of topic	No.	Name of topic
1	ESG governance system	15	Exhaust gas emissions
2	Risk and crisis management	16	Packaging materials
3	Business ethics and anti-corruption	17	Sewage/waste management
4	Supply chain compliance management	18	Occupational health and safety
5	Supply chain ESG management	19	Employee benefits and remuneration
6	Product safety and quality	20	Talent development and retention
7	Intellectual property rights	21	Diversity and equality
8	Technologies and innovations	22	Contributions to community
9	Responsible marketing	23	Public welfare and charity
10	Information security	24	Health accessibility/general benefits
11	Environmental management system	25	Industry development and win-win
12	Resource consumption management	26	Joint efforts against COVID-19 pandemic
13	Energy consumption		
14	Management of water resources		

03



Devoted to Product Development

On the one hand, the Group pursues technological innovations, actively integrates industry-leading resources at home and abroad, and learns from advanced technological experience to accelerate upgrading of products; on the other hand, the Group strives to build up a premium industry chain and continuously enhance the control on product quality. In addition, we also pay close attention to the after-sales feedback of the products, devoting to provide detailed and effective solutions to our customers.



Devoted to Product Development

3.1 Innovative development

Research & development and innovation

During the Reporting Period, despite the short-term decline in operating revenue of the Group due to the impact of the COVID-19 Pandemic, the Group continued to increase investment in research and development (“**R&D**”), focusing on expanding the R&D pipelines for innovative products of ophthalmology and medical aesthetics. During the Reporting Period, the R&D expenses reached approximately RMB126.47 million, representing an increase of approximately 8.95%, as compared to approximately RMB116.08 million in 2019. And the proportion of R&D expenses in operating revenue increased from approximately 7.28% in 2019 to approximately 9.55%.

While focusing on R&D investment, the Group also attaches importance to the management and supervision of R&D projects. In order to prevent R&D risks and enhance R&D management, the Group has established a series of R&D management schemes to govern the inception, procurement, evaluation, incentive and file management of R&D projects, and established a management system suitable to its practical circumstances on this basis. Besides, the Group incorporates the R&D quality management into the corporate quality management system, so that the quality management department can monitor the entire R&D process and assess the result. The project team organizes stage assessments and conclusion meetings regularly to ensure the smooth progress of project and ensure the risks are within control.

Devoted to Product Development

Intellectual property rights

The Group always attaches importance to the protection of intellectual property rights (IPRs), and protects the R&D achievements by formulating and implementing a series of practical and effective measures. During the Reporting Period, we strictly complied with the Patent Law of the People's Republic of China, the Trademark Law of the People's Republic of China and other relevant laws and regulations, and formulated our Trademark Management Regulation and Patent Management Regulation. The cooperative R&D agreements we signed with external universities and scientific research institutions were being fulfilled in a lawful manner. During the Reporting Period, the Group was not involved in any event of intellectual property dispute or intellectual property infringement.

- | | |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Risk management | <ul style="list-style-type: none">• We have established and implemented a series of internal systems relating to R&D, project declaration, and intellectual property management to identify, evaluate and control potential intellectual property risks in production, sales, and R&D activities. |
| System construction | <ul style="list-style-type: none">• We continue to improve the standardization of intellectual property rights. The Company and its subsidiaries NIMO and Shanghai Jianhua have all obtained intellectual property management system certification. |
| Regular trainings | <ul style="list-style-type: none">• We attach importance to the trainings on intellectual property rights. The Group organizes intellectual property management trainings every year for senior managers and employees from relevant departments such as R&D, project management, and quality control. |
| Internal audit | <ul style="list-style-type: none">• The audit department carries out self-evaluation on internal control every year. Any problem found during the self-evaluation of intellectual property management can be rectified in a timely manner. |

IPR protection measures

During the Reporting Period, the Group has made the following new achievements in the aspect of intellectual property rights:



Devoted to Product Development

3.2 Quality assurance

During the Reporting Period, the Group operated in strict compliance with the relevant medical laws and regulations, including the Pharmaceutical Administration Law of the People's Republic of China, Good Manufacturing Practices ("GMP") for Drugs, Good Clinical Practices for Drug Trials, Regulations on Supervision of Medical Devices, Administrative Measures on Production and Supervision of Medical Devices, Administrative Measures on Standards of Medical Devices, Administrative Rules on Quality of Good Clinical Trials for Medical Devices and Administrative Measures for Recall of Medical Devices, as well as relevant quality system standards such as ISO9001 Quality Management System Standards and ISO13485 Medical Device Quality Management System.

The quality management of the Group covers the entire lifecycle of the products from design, R&D, raw materials procurement, production and storage all the way through to sales operations and after-sales services. The Group has established a Quality Assurance Department ("QA") and a Quality Control Department ("QC"), which cooperate with the procurement department, R&D department, medical department, marketing department and other departments to fully implement the quality management system of the Company and its subsidiaries, ensuring the authenticity, reliability and traceability of the data in R&D and production links.

We pay due attention to quality-related training activities, aiming to continuously improve employees' quality awareness and operational skills. During the Reporting Period, the Group actively organized employees to participate in internal and external pharmaceutical quality-related trainings, which involved a series of trainings on medical device production and quality management related laws and regulations, aseptic production process, and pharmaceutical verification technologies. During the Reporting Period, the Group organized the relevant leaders of internal production departments to carry out three "flying inspections" within the Group, thereby ensuring normalized management on the quality system of the Group.

During the Reporting Period, the Group has not been subject to any administrative penalty or involved in any litigation cases relating to product quality or customer services.

Devoted to Product Development

Procurement of raw materials

Procuring high-quality raw materials is the basis for ensuring product quality. The Company and its subsidiaries have formulated their respective procurement management rules and policies in accordance with the requirements of GMP, ISO9001 Quality Management System Standards and the ISO13485 Medical Device Quality Management System and their respective procurement and business features to prevent any errors and malpractices in the course of the procurement and payment business, ensure that social and environmental risks in the procurement process will be subject to reasonable control, and improve the procurement management circulation and operation efficiency. The quality management department of the Company and its subsidiaries is responsible for assessing risks associated with materials adopted for relevant products. It selects qualified suppliers by inspecting their quality assurance systems and conducting on-site audits to assess the quality of their products. Our quality assurance staff are responsible for receiving, checking the quantities of, releasing, storing and managing purchased raw materials; and the laboratory staff are responsible for sampling and quality inspection of raw materials and issuing inspection reports.

During the Reporting Period, the Group had approximately 267 suppliers, of whom over 79% were located in China.

Production inspection

The Company and its relevant subsidiaries have formulated quality management system documents and made quality supervision records during the production process. The quality personnel of the Quality Assurance Department supervise the production process of each batch of pharmaceutical products. The semi-finished products are released after being signed by the quality personnel. All semi-finished and intermediate products are not allowed to enter the next step of process if they have not been inspected or failed to pass such inspections. The quality personnel make samples on each batch of products according to the regulated quantity and send them to the sample manager of the laboratory. The laboratory technicians conduct quality inspections on each batch of finished products in accordance with the inspection operating procedures and technical standards for each type of product, and then issue an inspection report based on the inspection results. The products that failed to pass the inspections are treated in accordance with relevant regulations. The quality personnel shall keep true and complete records of the quality supervision during the production process to ensure the traceability of product quality.

Traceability and recall

The traceability of its products is a great concern for the Group. We ensure that the product information is reliable and kept in record in every step from the arrival of raw materials to production, storage and transportation. We retain product sales records in accordance with the laws and regulations to meet the traceability requirements. We have also developed a set of detailed product recall procedures and rules in accordance with the requirements of relevant laws and regulations on recalls of pharmaceutical products and medical devices. We will conduct retrospective investigation and recall of products with quality defects in accordance with corresponding procedures. According to the seriousness of product defects, we divided product recalls into three levels. Recalls are systematically planned and proactively executed based the recall level and actual use of the products, so as to effectively protect consumers' interests and health.

During the Reporting Period, the Group had not recalled any product due to quality defects.

Devoted to Product Development

3.3 Responsible marketing

Advertising and labeling

The labels and instructions of all products of the Group are designed according to the Provisions on the Administration of Pharmaceutical Directions and Labels and the Provisions on the Administration of Instructions and Labels of Medical Devices. The advertisements of the products shall be published with the approval of the relevant drug administrative authorities in accordance with the requirements of the Advertising Law of the PRC, the Drug Administration Law of the PRC and the Regulations on the Supervision and Administration of Medical Devices, for ensuring that the content is true and accurate, and not misleading or deceptive. During the Reporting Period, the Group also organized employees to participate in the training related to the “Interim Measures for the Examination and Administration of Advertisements for Drugs, Medical Devices, Health Foods, and Formula Foods for Special Medical Purposes”.

Serving with heart

To continuously improve service quality of the Group, we visit customers regularly to provide them with the latest product information. We also arrange trainings related to product knowledge for customers. The Group organizes annual customer satisfaction surveys to understand customers' needs. Customer feedback and complaints are collected via multiple channels such as sales staff and adverse reaction reporting hotline. During the Reporting Period, the Group received two complaints regarding product quality and customer service. Upon receiving a feedback or complaint from a customer, we communicate immediately with relevant departments, and take prompt and effect measures to develop a satisfactory resolution for the customer based on the circumstances actually involved.

The Group attaches great emphasis to the regulation and management of adverse reactions and adverse events, and requires its subsidiaries to submit information on adverse reactions and events collected by them, actively conduct training on adverse reactions, and implement effective risk control measures in strict compliance with the Administrative System for Reporting and Monitoring Adverse Reactions of Drugs and the Administrative Measures for Monitoring and Reviewing Medical Equipment Adverse Events.

The Group places great emphasis on privacy protection for customers. Non-public information of our customers is protected in strict compliance with the requirements of relevant laws and regulations and confidentiality provisions under executed agreements, and only authorized employees can access such information.

04



Environmental Protection

As a biomedical enterprise, the Company regards environmental protection as an important part of its fulfillment of social responsibility. During the Reporting Period, the Group strictly complied with the Environmental Protection Law of the People's Republic of China, the Water Pollution Prevention and Control Law of the People's Republic of China, the Air Pollution Prevention and Control Law of the People's Republic of China and other relevant laws and regulations for environmental protection in the places where the Group operates its businesses, and continued to improve its environmental management capabilities to promote energy conservation and consumption reduction.



Environmental Protection

4.1 Environmental management

The Group strictly complies with the Environmental Protection Law of the People's Republic of China, the Energy Conservation Law of the People's Republic of China, the Water Pollution Prevention and Control Law of the People's Republic of China, the Air Pollution Prevention and Control Law of the People's Republic of China, the Law of the PRC on the Prevention and Control of Environmental Pollution Caused by Solid Waste, the Soil Pollution Prevention and Control Law of the People's Republic of China, the Law of the People's Republic of China on the Prevention and Control of Environmental Noise Pollution, and other relevant laws and regulations and industry standards relating to environmental protection. In order to ensure the orderly development of environmental management work, the Group has established an environmental management system in accordance with the environmental protection laws and regulations of different operating locations. In major production bases, the Group has deployed environment, health and safety (“EHS”) specialists who are responsible for guiding, inspecting, and urging the environmental protection work of various departments, and formulating emergency response plans for environmental emergencies to enhance our ability to respond to environmental emergencies. The Group practices standardized environmental management in all aspects including project R&D, project inception, and project operation to minimize the impact of corporate operations on the environment.

4.2 Energy conservation and consumption reduction

The Group attaches great importance to the conservation of resources and energy, and actively implements the development and operation concepts with energy conservation, emission reduction, and environmental protection. The Group strives to reduce the impact of its production and operation activities on the environment through measures such as upgrading environmental protection facilities, implementing energy-saving renovations, and enhancing employees' awareness of environmental protection and energy conservation.

Energy management

In respect of energy consumption, the energy resources consumed by the Group mainly include electricity, natural gas, externally purchased steam and fuel oil for motor vehicles. We reduce energy consumption in the production and operation of the Company through the renovation of environmental protection facilities and the optimization of project workflows. During the Reporting Period, the Company carried out low-nitrogen renovation for natural gas boilers to reduce nitrogen oxide emissions.

Environmental Protection

Water resources management

In respect of water resources utilization, the Group strictly complies with the laws and regulations of the places where it operates, and takes targeted water-saving measures based on its own operating conditions to improve the efficiency of water usage and eliminate the waste of water resources. The water consumed by the Group's production and operation mainly comes from municipal water supply, and there is no risk in obtaining suitable water sources. During the Reporting Period, Shanghai Likangrui used the first recycled water of the API (Active Pharmaceutical Ingredient) water production workshop to cool and dry the vacuum pumps, thereby saving the water used in production. In addition, Shanghai Likangrui added a water meter for each production unit to monitor the abnormal conditions of daily water usage, reducing unnecessary waste of water resources in different ways.

Packaging materials management

Reducing unnecessary packaging materials and paper usage will bring economic and environmental benefits to enterprises. The packaging materials used by the Group in production activities mainly include paper, plastic and glass. While ensuring product quality and transportation requirements, we continue to explore the technical applications for the saving of packaging materials and the optimization of work processes.

In the meantime, the Group regularly carries out trainings and promotions for green office among employees, improving employees' awareness of saving office resources and reducing unnecessary use of paper and other resources. During the Reporting Period, the energy and resources consumption and greenhouse gas emission by the Group are as follows:

Environmental Protection

Energy and Resource Consumption		
Type	Total Amount	Unit
Energy consumption		
Externally purchased electricity	19.77	GWh
Unleaded gasoline	111.90	Tonnes
Diesel	2.90	Tonnes
Externally purchased steam	10,588.63	Tonnes
Natural gas	1,555,197	Standard cubic meters
Integrated energy consumption	5,748.83	Tonnes of standard coal
Integrated energy consumption intensity	51.90	Standard coal (kg)/RMB10,000 of revenue*
Resource consumption		
Water consumption	229,074	Tonnes
Water consumption intensity	2.07	Tonnes/RMB10,000 of revenue*
Packaging materials	474.25	Tonnes
Packaging material intensity	4.28	Kilograms/RMB10,000 of revenue*
Greenhouse gas emissions		
Greenhouse gases (scope I) ¹	3,712	Tonnes of standard CO ₂ e
Greenhouse gases (scope II) ²	16,939	Tonnes of standard CO ₂ e
Total greenhouse gas emissions	20,651	Tonnes of standard CO ₂ e
Greenhouse gas intensity	0.19	Tonnes of standard CO ₂ e/RMB10,000 of revenue*

Note 1: Greenhouse gases (scope I) are generated from combustion of unleaded gasoline, diesel and natural gas.

Note 2: Greenhouse gases (scope II) are generated from the use of externally purchased electricity and steam.

* Being the operating revenue of the Company and its Domestic Subsidiaries during the Reporting Period.

Environmental Protection

4.3 Compliant emissions

The Group strictly complies with the emission standards in the places where it operates, regards compliant emissions as the basic requirement for fulfilling its environmental protection responsibility, and continues to explore and improve its emission management capabilities, so as to minimize the impact of its operations on the environment. We have established operating procedures to classify and dispose the main pollutants generated during the manufacturing process, such as waste gas, wastewater, noise and wastes, and strictly regulated the environmental protection records, handover and other series of processes. Meanwhile, we managed to reduce and eliminate pollution arising from all aspects of the manufacturing process by upgrading technology, improving the management of equipment and facilities and other measures.

Emissions from the operation of the Group mainly include waste gas, wastewater, and solid waste. During the Reporting Period, the Group's emissions data are as follows:

Energy and Resource Consumption		
Type	Total Amount	Unit
Waste gas		
Total waste gas emissions	25.42	Million cubic meters
SO ₂ emissions	0.05	Tonnes
NO _x emissions	0.94	Tonnes
VOCs emissions	0.22	Tonnes
Wastewater		
Total wastewater emissions	0.17	Million cubic meters
COD emissions	15.31	Tonnes
Ammonia nitrogen emissions	0.15	Tonnes
Non-hazardous waste		
Total non-hazardous waste produced	305.60	Tonnes
Intensity of non-hazardous waste produced	2.76	Kilograms/RMB10,000 of revenue*
Packaging waste produced ¹	11.41	Tonnes
Packaging materials recycled ²	95.77	Tonnes
Total domestic waste	198.42	Tonnes
Hazardous waste		
Total hazardous waste produced	55.92	Tonnes
Intensity of hazardous waste produced	0.50	Kilograms/RMB10,000 of revenue*

Note 1: The data caliber of the amount of packaging waste produced is the total amount of non-recyclable packaging waste (such as cartons, cardboards, bottles, etc.)

Note 2: The data caliber of the amount of packaging materials recycled is the total amount of recyclable packaging waste materials.

* Being the operating revenue of the Company and its Domestic Subsidiaries during the Reporting Period.

Environmental Protection

Waste gas emissions management

The waste gas emissions of the Group mainly include gas emissions from boilers, gas emissions from production process and gas emissions from laboratories. The Group strictly complies with the Boilers' Air Pollution Discharge Standards, the Pollutant Emission Standards for Biopharmaceutical Industry, and the Comprehensive Standards for Air Pollutant Discharge and other relevant standards and laws and regulations on waste gas emissions in its operating locations. On the basis of compliant emissions, the Group is committed to reducing the generation of pollutants and improving its technical capabilities of waste gas treatment. After collecting the waste gas emissions from boiler combustions, the Company will organize emissions complying with required standards at high altitude. After collection and treatment of waste gas emissions from production process and laboratories, emissions complying with required standards at high altitude will be arranged.

Regularly replace the odor spray facility for volatile organic compounds ("VOC") of the sewage plant to avoid the risk of waste gas treatment due to aging of equipment

The quality inspection room is equipped with an activated carbon adsorption device, so that the VOC generated by the fume hood and universal exhaust hood enters the activated carbon adsorption device for purification treatment, thus reducing VOC emissions


Measures for waste gas emission reduction

Wastewater discharge management

The wastewater produced by the Group includes domestic sewage, R&D and production wastewater, and circulation cooling system sewage. We strictly control the compliant discharge of wastewater in accordance with the relevant requirements of the Water Quality Standards for Sewage Discharged into Urban Sewers and the Comprehensive Standards for Wastewater Discharge in our operation locations. Production wastewater and domestic sewage are collected into the sewage treatment stations in the plant for relevant treatment and then discharged into the municipal pipeline network. The stations carry out online and regular monitoring on wastewater indicators to prevent excessive discharge. In addition, the Group has implemented rainwater and sewage diversion measures to separate, collect and discharge wastewater of different water quality, so as to reduce the environmental impact of the wastewater generated from production and operation.

Environmental Protection

During the Reporting Period, the Group comprehensively strengthened the management of wastewater discharge. On the basis of ensuring the treatment capacity of sewage treatment stations, the Group further improved its compliance capacity of sewage discharge through monitoring evaluation and technical optimization.



Measures for wastewater discharge management

Solid waste management

In respect of hazardous waste disposal, the Group takes the Standards for Pollution Control on Hazardous Waste Storage as the guidance, and strictly implements the standards for hazardous waste treatment, thus realizing compliant management on the entire process from generation, statistics, application, approval, to transfer and disposal of hazardous waste. The proper treatment of hazardous waste greatly reduces the impact on the environment. Regarding the treatment of general industrial solid wastes, the Group complies with the Standards for Pollution Control on the Storage and Disposal Site for General Industrial Solid Wastes and disposes of general industrial solid wastes as waste materials for external treatment, and delivers domestic wastes to the sanitation department for regular removal.

On the basis of compliant disposal, the Group has established its Wastes Management Regulation with reference to the requirements of Regulations of Shanghai Municipality on the Administration of Domestic Wastes and other standards, to further standardize and optimize the waste management work and procedures within the Group and reduce the generation of wastes. We have set up centralized disposal sites for solid wastes to classify different types of solid wastes for storage, and further improved our solid waste management level through the standardized improvement and guidance of the procedures covering records, handover, supervision and optimization.


In order to strengthen the staff's awareness of saving and build a culture of sustainable development, the Group implements a fixed meal system in the staff canteen, and each person selects foods according to his/her needs to ensure the implementation of the "No-waste Plan". All wastes from the kitchens, production sites and construction sites are removed and treated by professional units to ensure the best use of waste materials and improve the secondary utilization of resources on the basis of eliminating waste.

Environmental Protection

Noise management

The Group has adopted various measures, including exit silencing device, base vibration isolation device and construction noise isolation device, according to the characteristics of the sources of different types of noises. According to the testing results, the noises produced by the Group's major production bases, namely, the Company, Shanghai Qisheng and Shanghai Likangrui have complied with the standard limits specified in the Environmental Noise Emission Standards for Industrial Enterprises during the Reporting Period.

05




Harmonious Team

Human resources are important strategic resources of the Company. The Group adheres to the “people foremost” principle and firmly believes that “people” are the foundation for the Group’s sustainable and successful development. We protect the basic rights and interests of every employee through our diverse and fair employment policy, scientific training system, reasonable incentive measures and healthy working environment, and strive to create a win-win situation for employees and the Group to grow together.



Harmonious Team


Number of employees by gender



Male
682, 50%

Female
692, 50%

Number of employees by age



20 and below
6, 0.5%

21-30
330, 24.0%

31-40
529, 38.5%

41-50
308, 22.4%

50 and above
201, 14.6%

5.1 Overview of employees

The Group strives to create a fair and just employment environment for employees. We strictly comply with the Labor Law of the People's Republic of China, the Labor Contract Law of the People's Republic of China, the Regulations on Labor Protection of Female Workers, the Social Insurance Law of the People's Republic of China, the Work Safety Law of the People's Republic of China, the Occupational Disease Prevention Law of the People's Republic of China, and local laws and regulations at the places where the Company and its subsidiaries are located, and also establish internal systems such as the Staff Handbook, the Professional Titles Management Regulation, and the Key Positions Management Regulation, laying down provisions regarding the working hours, paid and unpaid leaves, the conditions on cancelling and terminating labor relations, payment of salaries, and recruitment and promotion. We regularly review the effectiveness of our measures on employment, occupational health and safety, child labor and forced labor.

The Group is committed to eliminating discrimination by race, gender, age, background, beliefs or other factors, and to creating a diverse, equal, and fair development environment for all employees. Before entering into an employment contract with a prospective employee, we verify his/her identity and age by checking his/her identity card and academic credentials to completely eliminate illegal recruitment practices such as child labor and forced labor.

During the Reporting Period, the Group did not engage in any illegal employment practices involving child labor or forced labor.

During the recruitment process, the Group focuses on optimizing its talent structure and improving the Company's overall talent quality, thereby promoting the sustainable development of the Company. As at the end of the Reporting Period, the Group had a total of 1,374 employees.

5.2 Development of Employees

The growth and development of employees is the foundation for the Company to maintain its long-lasting success. Adhering to the talent development concept of “appointing people based on their merits, and making the best use of their talents”, the Group builds its talent echelon, stimulates employees’ potential, and improves employees’ comprehensive capabilities, so as to help them realize their maximum values in the Company. During the Reporting Period, in respect of human resources management, we initially established a business cooperation management model, and strengthened the cooperation between the human resources department and other business departments in the aspects of talent discovery, capability training, and employee development.

Remuneration and benefits

We are well aware that scientific and reasonable remuneration and work benefits are important guarantees for the stable development of employees. The Group persists in analyzing employees’ remuneration based on market conditions every year, thus continuously optimizing the remuneration structure to make it more competitive in the market, and continuously promoting the renovation and transformation of the Group’s canteens, dormitories and offices to improve the welfare and benefits for employees.


Multi-channel recruitment

The Group’s human resources department closely cooperates with the business departments to comprehensively assess and control the recruitment of talents in terms of their professional competence, work skills and career development expectations. We efficiently introduce diversified talents through campus recruitment, intermediary agency recommendation, social recruitment, internal recommendation and other channels.

Trainings for employees

The Group attaches great importance to the career development of employees. We strive to build and improve a training system covering all employees and actively create a learning atmosphere within the corporate. The Group has formulated a relatively complete training management system to provide institutional guarantees for employees to participate in the Company’s internal and external trainings. While encouraging all subsidiaries and departments to organize and carry out their diversified


Number of employees by region



China mainland
1,200, 87%

Hong Kong,
Macau, Taiwan
and overseas
174, 13%

Number of employees by education



Ph.D
27, 2%

Master
117, 8%

Bachelor
453, 33%

Junior college
or below
777, 57%

Harmonious Team

trainings, the Company also formulates annual training plans based on the industry development conditions, actual situation of the Company, and the specific needs of employees. Through the “Haohai Forum”, the Group arranges internal related business leaders to conduct theme trainings, providing a stable and professional platform to employees for knowledge sharing, professional exchanges, and self-exhibition; the Group also invites external compliance experts in the industry to provide more professional and cutting-edge knowledge and information regarding the industry and compliance to our employees.

During the Reporting Period, the Group’s training programs were conducted both offline and online. The training contents included induction training for new employees, training on medical laws, regulations and policies, training on intellectual property management and protection, training on internal information transmission and confidentiality within the Company, training on professional knowledges about biological materials and medical products, training on job skills, training on professional ethics, and other personalized trainings on management ability and innovative thinking.

5.3 Health and safety

Safety management

The Group attaches great importance to the health and safety of employees. We strictly comply with the Production Safety Law of the People’s Republic of China, the Occupational Disease Prevention Law of the People’s Republic of China, the Work Injury Insurance Regulations and other relevant laws and regulations, and formulate the Production Safety Management System and other production safety regulations in accordance with the requirements of relevant laws, regulations and quality management systems.

The Company has passed the occupational health and safety management system certification (GB/T 45001-2020/ISO45001:2018). Guided by the requirements of the occupational health and safety management system, the Company implements strict monitoring and management on the workplaces, regularly carries out safety inspections and formulates optimal emergency response plans, so as to ensure the achievement of production safety goals.

In respect of safety culture construction, the Group has continuously improved the safety trainings for employees, especially the trainings about EHS-related laws and regulations and EHS management objectives. The Group carries out emergency drills regularly, and always implements safety trainings and education throughout the entire process of safe production. During the Reporting Period, the Group organized fire emergency drills for employees and emergency drills for leakage of hazardous chemicals, and provided corresponding safety trainings for employees in offices, workshops, warehouses, and engineering departments. Through various activities and trainings, all employees can quickly learn safety knowledges, and comprehensively enhance their own safety awareness.

During the Reporting Period, there was no workplace fatal injury accident within the Group. Lost working hours due to work-related injury amounted to 178 hours. For work-related accidents, the Group proactively handled work-related injury identification, labor ability identification, and work-related injury claims for injured employees, and conducted safety education and trainings to relevant employees to avoid recurrence of the accidents.

During the COVID-19 pandemic period, we immediately purchased masks, forehead thermometers, disinfectants, gloves, alcohol and other daily epidemic prevention materials to meet and guarantee the materials requirements of the employees on duty and for resumption of work. We actively responded to the government's call to implement the resumption of work in batches according to the requirements of the local government agencies, and closely tracked and recorded the physical health conditions of our employees, disinfected the office premises every day, and arranged online trainings on epidemic prevention and control to ensure the health of every employee.

5.4 Caring for staff

Upholding the idea of people foremost, the Group cares about the physical and psychological health of our employees, provides them with diverse welfare and care, and encourages them to strike a balance between work and life. We endeavor to create a comfortable working environment for our employees through actively improving employee welfare and benefits, organizing various caring activities, teambuilding activities and festive season celebrating activities.

We actively encourage employees to feedback effective information from the perspective of work, enhance the communications between managers and employees, and explore various feasible suggestions that are beneficial for improving the business management of the Group. We also actively listen to the voices of employees. On the Company's WeChat platform, we have set up an online compliant channel "Employee's Voice" to receive problems encountered by employees during their work and life, and make efforts to settle those problems, so as to enhance employees' sense of belonging.

During the Reporting Period, although the Group was unable to organize large-scale teambuilding and travel activities due to the COVID-19 pandemic, the Company and its subsidiaries and various departments organized their teambuilding activities to enhance cohesion in an orderly manner under the conditions that epidemic prevention requirements are met and safety is ensured. At the end of 2020, the Group held an online annual ceremony for the first time, connecting the Group's employees located in different places across the country through online video, and celebrating the New Year together by gathering online. Through our corporate official account on WeChat, the Group demonstrated the achievements of outstanding employees and outstanding teams, and showed the Group's development in the previous year, thereby enhancing the employees' sense of belonging and collective honor.

During the Reporting Period, NIMO held the "Fengcai Cup" speech contest, with market, technology and management as the topics of the speech, providing employees with a platform to give impromptu speeches and encouraging them to have a positive mental outlook.

06



Heart in Community

The Group has been extending our care for the society in our steady business development. On the basis of ensuring the safety of product quality and bringing benefits to patients, we pay taxes according to the law, focus on social public welfare, and perform our social responsibilities. Meanwhile, as a pharmaceutical enterprise, we take an active part in the industry associations, assist in formulating industry standards, and attend industry meetings to proactively promote the development of the industry.



6.1 Charity donations

While pursuing economic development, the Group does not forget its social responsibilities as a biomedical enterprise. During the Reporting Period, the Group donated a total of RMB844,256.70 in social public welfare activities.

“Bright Eyes for 100 People Public Welfare Action”

In November 2020, the “Bright Eyes for 100 People Public Welfare Action” jointly launched by the Group in cooperation with Zhejiang Women and Children’s Foundation, Zhejiang Light Charity Foundation, Eye Hospital of Wenzhou Medical University, and Zhijiang Branch of Zhejiang Eye Hospital held an opening ceremony in Zhijiang Branch of Zhejiang Eye Hospital. This activity aims to help 100 women with ultra-high myopia in Zhejiang Province to improve their vision by taking PRL implant surgeries free of charge. Hangzhou Aijinglun, a subsidiary of the Company, donated 200 pieces of “Yijing” PRL lenses for this activity and donated RMB268,724.00 in cash.

6.2 Contributions to the industry

We are well aware that the long-term and healthy development of an enterprise is inseparable from the development and progress of the industry. While persisted in its own sustainable development, the Group always pays attention to the industry trends, actively organizes and attends industry activities and seminars, strengthens the exchanges and cooperation with the industry peers, and is committed to promoting the progress and development of the entire industry.

During the Reporting Period, the Group was invited to participate in industry seminars on many occasions, and organized academic discussions during the seminars, exhibited the latest products and R&D projects at the seminars, and published many papers on different journals.



Published paper: Verification of the microbial limit inspection method for cross-linked sodium hyaluronate (Shanghai Medical & Pharmaceutical Journal, Vol. 41, Issue 13, 2020)



Published article: On example for diagnosis of branch retinal artery occlusion by multispectral imaging (Journal of Imaging Research and Medical Applications, April 2020, Volume 4, Issue 8)



Participated in the formulation of industry standard: Medical carboxymethyl chitosan YY/T0953-2020



Participated in the formulation of industry standard: Tissue engineering medical device product chitosan YY/T1699-2020.

Heart in Community

Participated in the 25th Congress of Chinese Ophthalmological Society (CCOS)

In November 2020, the 25th Congress of Chinese Ophthalmological Society (CCOS) organized by the Chinese Medical Association and the Chinese Ophthalmological Society was successfully held. The Group's five therapeutic products for cataract, optometry, refraction, ocular surface and fundus were exhibited together, and many experts and scholars in the field of ophthalmology were invited to bring professional academic sharing activities.


Participated in the 20th International Congress of Ophthalmology and Optometry China (COOC 2020)

In September 2020, the Group participated in the 20th International Congress of Ophthalmology and Optometry China (COOC 2020) held in Shanghai. At this conference, our "Yijing" PRL product made its first public appearance at a large-scale academic conference, which intuitively demonstrated its performance and efficacy to the audience by simulating surgical procedures and answering clinical questions by experts.

6.3 Assistance to fight against COVID-19 pandemic

The COVID-19 pandemic broke out in early 2020, and spread across the country quickly. When carrying out epidemic prevention and control and resuming work and production on time, the Group actively cooperated with local communities for epidemic prevention and control. In addition, some of the gloves, masks and protective outfits were donated to the local communities to protect frontline epidemic prevention workers.

At the end of 2020, in response to the Company's efforts during the COVID-19 pandemic prevention and control period, the Shanghai Medical Instrument Trade Association awarded the Company a certificate of honor.



Measures for resumption of work and production

Appendix Content Index of ESG Reporting Guide of the Stock Exchange

Subject Area, Aspects, General Disclosures and KPIs		Disclosed in
A. Environmental		
Aspect A1	Emissions	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	Environmental Protection: Environmental management
KPI A1.1	The types of emissions and respective emission data.	Environmental Protection: Compliant emissions
KPI A1.2	Greenhouse gas emissions in total (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Environmental Protection: Energy conservation and consumption reduction
KPI A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Environmental Protection: Compliant emissions
KPI A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Environmental Protection: Compliant emissions
KPI A1.5	Description of measures to mitigate emissions and results achieved.	Environmental Protection: Compliant emissions
KPI A1.6	Description of how hazardous and non-hazardous wastes are handled, reduction initiatives and results achieved.	Environmental Protection: Compliant emissions
Aspect A2	Use of Resources	
General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials. <i>Note: resources may be used in production, in storage, transportation, in buildings, electronic equipment, etc.</i>	Environmental Protection: Energy conservation and consumption reduction
KPI A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	Environmental Protection: Energy conservation and consumption reduction

Appendix Content Index of ESG Reporting Guide of the Stock Exchange

Subject Area, Aspects, General Disclosures and KPIs		Disclosed in
KPI A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	Environmental Protection: Energy conservation and consumption reduction
KPI A2.3	Description of energy use efficiency initiatives and results achieved.	Environmental Protection: Energy conservation and consumption reduction
KPI A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency initiatives and results achieved.	Environmental Protection: Energy conservation and consumption reduction
KPI A2.5	Total packaging materials used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	Environmental Protection: Energy conservation and consumption reduction
Aspect A3	Environment and Natural Resources	
General Disclosure	Policies on minimizing the issuer's significant impact on the environment and natural resources.	Environmental Protection: Environmental management
KPI A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	Environmental Protection: Energy conservation and consumption reduction

Appendix Content Index of ESG Reporting Guide of the Stock Exchange

Subject Area, Aspects, General Disclosures and KPIs		Disclosed in
B. Social		
Employment and Labor Practices		
Aspect B1	Employment	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	Harmonious Team: Overview of employees, Development of employees
KPI B1.1	Total workforce by gender, employment type, age group and geographical region.	Harmonious Team: Overview of employees (partly disclosed)
KPI B1.2	Employee turnover rate by gender, age group and geographical region.	To be disclosed in the future
Aspect B2	Health and Safety	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	Harmonious Team: Health and safety
KPI B2.1	Number and rate of work-related fatalities.	Harmonious Team: Health and safety
KPI B2.2	Lost days due to work injury.	Harmonious Team: Health and safety
KPI B2.3	Description of occupational health and safety measures adopted, how they are implemented and monitored.	Harmonious Team: Health and safety
Aspect B3	Development and Training	
General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities. Training refers to vocational training. It may include internal and external courses paid by employers.	Harmonious Team: Development of employees

Appendix Content Index of ESG Reporting Guide of the Stock Exchange

Subject Area, Aspects, General Disclosures and KPIs		Disclosed in
KPI B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	To be disclosed in the future
KPI B3.2	The average training hours completed per employee by gender and employee category.	To be disclosed in the future
Aspect B4	Labor Standards	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labor.	Harmonious Team: Overview of employees
KPI B4.1	Description of measures to review employment practices to avoid child and forced labor.	Harmonious Team: Overview of employees
KPI B4.2	Description of steps taken to eliminate such practices when discovered.	To be disclosed in the future
Operating Practices		
Aspect B5	Supply Chain Management	
General Disclosure	Policies on managing environmental and social risks of the supply chain.	Devoted to Product Development: Quality assurance
KPI B5.1	Number of suppliers by geographical region.	Devoted to Product Development: Quality assurance
KPI B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, how they are implemented and monitored.	Devoted to Product Development: Quality assurance

Appendix Content Index of ESG Reporting Guide of the Stock Exchange

Subject Area, Aspects, General Disclosures and KPIs		Disclosed in
Aspect B6	Product Responsibility	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	Devoted to Product Development: Responsible marketing
KPI B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	Devoted to Product Development: Quality assurance
KPI B6.2	Number of products and service related complaints received and how they are dealt with.	Devoted to Product Development: Responsible marketing
KPI B6.3	Description of practices relating to observing and protecting intellectual property rights.	Devoted to Product Development: Innovative development
KPI B6.4	Description of quality assurance process and recall procedures.	Devoted to Product Development: Quality assurance
KPI B6.5	Description of consumer data protection and privacy policies, how they are implemented and monitored.	Devoted to Product Development: Responsible marketing

Appendix Content Index of ESG Reporting Guide of the Stock Exchange

Subject Area, Aspects, General Disclosures and KPIs		Disclosed in
Aspect B7	Anti-corruption	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	Dedicated to Corporate Governance: Company governance
KPI B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the Reporting Period and the outcomes of the cases.	Dedicated to Corporate Governance: Company governance
KPI B7.2	Description of preventive measures and whistle-blowing procedures, how they are implemented and monitored.	Dedicated to Corporate Governance: Company governance
Community		
Aspect B8	Community Investment	
General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	Heart in Community
KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labor needs, health, culture, sport).	Heart in Community
KPI B8.2	Resources contributed (e.g. money or time) to the focus area.	Heart in Community